How gut microbiome testing has changed over the last 10 years

A decade ago, looking at the gut microbiome meant looking through a keyhole. Today, we can see the whole room. Here is how we got here — and where the field is heading next.

Ten years ago, microbiome science was rapidly revealing the gut microbiome as an important contributor to digestive, metabolic and immune health. But many commonly used testing approaches were still limited in what they could show.

The standard approach was 16S rRNA gene sequencing (16S). It works by reading selected regions of a single marker gene shared across bacteria and archaea, then uses sequence similarity to estimate which organisms are present. It was an important first step, helping researchers and clinicians describe broad patterns in microbial community composition.

But 16S had clear limitations. Resolution typically stopped at the genus or higher taxonomic levels, so two clinically distinct species could be grouped together. It detected bacteria but largely overlooked archaea and was not designed to profile fungi, other eukaryotes, or viruses. And it provided limited insight into microbial function — it could suggest who was in the community, but not what that community was capable of doing.

For practitioners and researchers, this meant working with a broad-brush picture of the microbiome and a fair amount of inference. The science was moving quickly but the available testing methods still left much of the microbiome’s complexity out of view.

The milestones that moved the field forward

Several shifts over the past decade changed what was possible.

From marker genes to shotgun metagenomics

• Metagenomic sequencing reads the genetic content across the entire sample rather than focusing on a single marker gene. This has made high-resolution profiling possible, down to species-level and even strain-level. Instead of grouping organisms loosely, it became possible to identify them with far greater precision.

From composition to function

• By sequencing most of the genetic content in a sample, metagenomics can also reveal the functional potential of the community: the metabolic pathways present, and the capacity to produce compounds such as short-chain fatty acids that matter for gut health. The question shifted from “who is here?” to “what can this community do?”

From bacteria-focused profiles to a broader community view

• As methods matured, testing began to account for the wider microbial community, including archaea, fungi and viruses, bringing the field closer to a more complete picture of the gut microbiome.

From exploratory research to more standardised, clinically oriented tools

• Perhaps one of the most significant changes has been the growing emphasis on standards: validated methods, reproducible analysis, quality-controlled reporting and clinically meaningful interpretation. Microbiome testing is evolving from exploratory profiling toward more standardised, clinically oriented tools that can provide additional context for healthcare discussions, while the evidence base for routine clinical use continues to develop.

Where the standard sits today

This is the evolution Microba was built to advance. Our metagenomic technology reflects the shift toward more comprehensive, quality-controlled microbiome analysis: testing that identifies microbial community members with high precision and reports on the functional capacity of the gut microbiome, not composition alone.

It is the difference between a list of names and a more integrated understanding of a community — between identifying which microbes are present and understanding what they may be contributing to a person’s health. For practitioners, that means additional evidence to support more informed conversations. For patients living with persistent gastrointestinal symptoms, it can provide scientifically grounded insight to discuss with their healthcare practitioner alongside the broader clinical picture.

The progress of the last decade has been considerable. The depth, resolution and rigour now available with metagenomic microbiome analysis would have been difficult to imagine when 16S was the default.

Seeing the whole picture

The trajectory is clear. Each milestone has moved the field from a narrow, partial view toward a more complete one — from single marker gene profiling to the whole-metagenome analysis, from lists of organisms to the function of microbial communities, from exploratory research toward more standardised, clinically oriented tools.

The next decade will be about turning that depth into more meaningful, actionable understanding for the practitioners and patients who rely on it. The direction of travel remains the same: to move beyond the keyhole and see the whole picture.